Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAM | P19021 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801192 | 0.92 | CCR6 (0.54) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL4692471 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL782974 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL2787581 | 0.84 | CCR6 (0.50) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL11298253 | 0.83 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL28460823 | 0.81 | CCR6 (0.55) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL19382504 | 0.80 | CCR6 (0.50) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL11257530 | 0.80 | CCR6 (0.47) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL13049197 | 0.80 | CCR6 (0.50) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 | |
| SCHEMBL782973 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1CCR6PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001891-B1 | BUPRENORPHINE DERIVATIVES AND USES THEREOF | RB PHARMACEUTICALS LTD (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-7964610-B2 | Buprenorphine derivatives and uses thereof | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100234412-A1 | Buprenorphine Derivatives and Uses Thereof | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| EP-2001891-A1 | BUPRENORPHINE DERIVATIVES AND USES THEREOF | Reckitt Benckiser Healthcare (UK) Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110636-A1 | BUPRENORPHINE DERIVATIVES AND USES THEREOF | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |
| US-4596791-A | Containing heterocyclic fused ring | USV PHARMACEUTICAL CORP. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0121830-A2 | Substituted dipeptides as antihypertensives | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234412-A1 | Buprenorphine Derivatives and Uses Thereof | OPRD1, OPRK1, OPRM1 | ALDH1A1 329/4885MAPK1 2736/4885L3MBTL1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.